| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 05/30/2002 | CA2428885A1 Method of separating extra-chromosomal dna from other cellular components |
| 05/30/2002 | CA2427340A1 Cyp1b1 nucleic acids and methods of use |
| 05/30/2002 | CA2421151A1 Modified vaccinia ankara virus variant |
| 05/29/2002 | EP1209229A1 Gene involved in schizophrenia |
| 05/29/2002 | EP1208381A2 Proteins, genes and their use for diagnosis and treatment of breast cancer |
| 05/29/2002 | EP1208380A2 Cancer associated antigens and uses therefor |
| 05/29/2002 | EP1208242A1 Antisense modulation of pepck-mitochondrial expression |
| 05/29/2002 | EP1208235A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 05/29/2002 | EP1208234A1 Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids |
| 05/29/2002 | EP1208228A2 Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| 05/29/2002 | EP1208218A2 Methods and compositions for delivery of pharmaceutical agents |
| 05/29/2002 | EP1208217A1 Antibody dependent enhancement (ade) of alphavirus infection |
| 05/29/2002 | EP1208212A1 Fibrin sealant as a transfection/transformation vehicle for gene therapy |
| 05/29/2002 | EP1208199A2 DNA CODING FOR $g(b)-TUBULIN AND USE THEREOF |
| 05/29/2002 | EP1208198A2 Egfh2 genes and gene products |
| 05/29/2002 | EP1208197A1 Iren protein, its preparation and use |
| 05/29/2002 | EP1208196A1 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof |
| 05/29/2002 | EP1208195A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/29/2002 | EP1208191A1 13 human colon and colon cancer associated proteins |
| 05/29/2002 | EP1208133A1 Copolymers for the transfer of nucleic acids to the cell |
| 05/29/2002 | EP1208115A2 Feline interleukin-12 as an immune stimulant |
| 05/29/2002 | EP1208114A2 Induction of programmed cell death by n5 gene |
| 05/29/2002 | EP1208112A1 Drug target isogenes: polymorphisms in the 5-hydroxytryptamine receptor 1a gene |
| 05/29/2002 | EP1208110A1 Antisense modulation of focal adhesion kinase expression |
| 05/29/2002 | EP1208086A1 Benzamide formulation with histone deacetylase inhibitor activity |
| 05/29/2002 | EP1207909A2 Method for coupling molecules |
| 05/29/2002 | EP1207877A1 Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids |
| 05/29/2002 | EP1207755A1 Methods of and compositions for inhibiting the proliferation of mammalian cells |
| 05/29/2002 | EP0774974B1 Nucleic acid vaccine |
| 05/29/2002 | EP0752002B1 Inhibition of arterial smooth muscle cell proliferation |
| 05/29/2002 | DE10057014A1 Preparing target cell-specific pharmaceutical, useful for gene therapy of e.g. cancer, by cloning expression control sequences having higher activity in target cell |
| 05/29/2002 | DE10056210A1 Virales Expressionssystem Viral expression system |
| 05/29/2002 | DE10055383A1 Verwendung des humanen LRP/MVP Promotors für einen Therapie-induzierbaren Vektor Using the human LRP / MVP promoter for a therapy-inducible vector |
| 05/29/2002 | CN1351664A DNA sequence and recombination production of a graminae allergen |
| 05/29/2002 | CN1351661A Compounds |
| 05/29/2002 | CN1351656A Human liver progenitors |
| 05/28/2002 | US6395961 Gene transfer in chickens by introduction of DNA into muscle in ovo |
| 05/28/2002 | US6395960 A genetically engineered rodent; diagnosis and therapy for alzheimer's disease |
| 05/28/2002 | US6395888 High affinity nucleic acid ligands of complement system proteins |
| 05/28/2002 | US6395883 Soluble morphogenic protein complex compositions of matter |
| 05/28/2002 | US6395876 High-affinity tryptophan transporter |
| 05/28/2002 | US6395712 Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy |
| 05/28/2002 | US6395544 Antisense modulation of BCAS1 expression |
| 05/28/2002 | US6395530 LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies |
| 05/28/2002 | US6395519 Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer |
| 05/28/2002 | US6395511 Nuclelotide sequences coding regulatory protein; for usein treatment of bone disorders |
| 05/28/2002 | US6395510 Vertebrate apoptosis gene: compositions and methods |
| 05/28/2002 | US6395498 Methods of identifying compounds that modulate body weight using the OB receptor |
| 05/28/2002 | US6395492 Derivatized oligonucleotides having improved uptake and other properties |
| 05/28/2002 | US6395474 Peptide nucleic acids |
| 05/28/2002 | US6395029 Sustained delivery of polyionic bioactive agents |
| 05/23/2002 | WO2002040715A2 Molecules for disease detection and treatment |
| 05/23/2002 | WO2002040700A2 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | WO2002040693A1 Adenoviral replicons |
| 05/23/2002 | WO2002040678A1 Small acid-soluble spore protein and uses thereof |
| 05/23/2002 | WO2002040674A2 '67118', '67067' and '62092', human proteins and methods of use thereof |
| 05/23/2002 | WO2002040673A2 Compositions and methods relating to lung specific genes and proteins |
| 05/23/2002 | WO2002040665A2 Complementing cell lines |
| 05/23/2002 | WO2002040635A2 HUMAN RNase H1 MUTANTS |
| 05/23/2002 | WO2002040629A2 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/23/2002 | WO2002040540A2 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 05/23/2002 | WO2002040538A2 Regulation of human nmda receptor |
| 05/23/2002 | WO2002040517A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040059A2 Methods and compositions for inducing cell-mediated immune responses |
| 05/23/2002 | WO2002040038A2 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | WO2002040037A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002039955A2 Biodegradable mixed polymeric micelles for drug delivery |
| 05/23/2002 | WO2002039885A2 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 05/23/2002 | WO2001092552A3 Method for the purification of alphavirus replicon particles |
| 05/23/2002 | WO2001087346A3 Dendritic cells loaded with toxic substances |
| 05/23/2002 | WO2001085961A3 Human caspase-12 |
| 05/23/2002 | WO2001083730A3 Recombinant lentiviral vectors pseudotyped in envelopes containing filovirus binding domains |
| 05/23/2002 | WO2001083720A3 23686, a novel human aminotransferase and uses therefor |
| 05/23/2002 | WO2001083715A3 Derivation of midbrain dopaminergic neurons from embryonic stem cells |
| 05/23/2002 | WO2001083513A3 Antisense modulation of inhibitor of dna binding-1 expression |
| 05/23/2002 | WO2001082948A3 Uses of tgap7 for the modulation of leucocyte activation |
| 05/23/2002 | WO2001081577A3 Dna encoding the prost 03 polypeptide |
| 05/23/2002 | WO2001079444A3 Albumin fusion proteins |
| 05/23/2002 | WO2001078753A3 Therapeutic uses for mesenchymal stromal cells |
| 05/23/2002 | WO2001076637A3 Peptide conjugates for drug delivery |
| 05/23/2002 | WO2001072837A3 Methods of modulating drug clearance mechanisms by altering sxr activity |
| 05/23/2002 | WO2001072294A3 Method of treating hepatitis delta viral infection |
| 05/23/2002 | WO2001068866A3 Estrogen-regulated unconventional myosin-related protein: compositions and methods of use |
| 05/23/2002 | WO2001063295A3 Dpi-6, a therapeutic biomarker in neurological disorders |
| 05/23/2002 | WO2001053506A3 Virus strains for the oncolytic treatment of cancer |
| 05/23/2002 | WO2001049316A3 Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization |
| 05/23/2002 | WO2001047946A9 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 05/23/2002 | WO2001040271A9 Cancer associated antigens and uses therefor |
| 05/23/2002 | WO2001038346A3 Short peptides to target epithelial cells |
| 05/23/2002 | WO2000053210A9 Methods of treatment and prevention of restenosis |
| 05/23/2002 | US20020062489 Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same |
| 05/23/2002 | US20020062488 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus |
| 05/23/2002 | US20020062121 Perfusion apparatus and methods for pharmaceutical delivery |
| 05/23/2002 | US20020061862 Inducible nitric oxide synthase for treatment of disease |
| 05/23/2002 | US20020061860 Antisense oligonucleotide inhibition of specific histone deacetylase isoforms |
| 05/23/2002 | US20020061848 An specific polypeptides comprising a Chlamydia antigen and the use of such polypeptides for the serodiagnosis and treatement of Chlamydia infection |
| 05/23/2002 | US20020061843 Use of mCRP for delivery of materials into cells |
| 05/23/2002 | US20020061834 Human G-protein Chemokine receptor (CCR5) HDGNR10 |
| 05/23/2002 | US20020061592 Liquid or frozen mixture for use in maintaince of viral particles; for use in gene therapy |
| 05/23/2002 | US20020061590 Nucleotide sequences coding transport protein for use treatment of hematopoietic and immunological defects |